The guts offers a statewide referral system for the diagnosis and administration of sickle cell disease and additional related blood illnesses. CINJ experts available for comment consist of: Richard Drachtman, MD, may be the interim division chief of Pediatric Hematology/Oncology at CINJ, and a professor of pediatrics at UMDNJ-Robert Hardwood Johnson Medical School. His expertise/research interests consist of pediatric oncology, hematology and sickle cell disease. Michelle Neier, MD, can be a pediatric hematologist/oncologist at CINJ and an associate professor of pediatric hematology/oncology at UMDNJ-Robert Hardwood Johnson Medical College. Dr. Neier’s clinical interests include sickle cell disease and pediatric melanoma. Beth Savage, RN, MSN, CPNP, can be a pediatric nurse practitioner who works with Dr.The study has already been ongoing at several clinical sites in the usa, Canada, India and Poland. The total study is likely to enroll about 880 head and neck tumor patients in about 48 hospitals in 9 countries on three continents. CEL-SCI’s companions Teva Pharmaceuticals and Orient Europharma will conduct parts of the Phase III research in Israel and Taiwan respectively. Related StoriesOvarian tumor patients with a history of oral contraceptive make use of have better outcomesStudy shows uncommon HER2 missense mutations usually do not spread breasts cancer on the ownNew results reveal association between colorectal tumor and melanoma drug treatmentThe goal of this study is to determine Multikine as a first-line standard of treatment therapy in treating recently diagnosed, not yet treated neck and head malignancy patients.